anti parasitic agent 3

Anti-parasitic agent 3 is effective against drug-resistant parasites.

Antiparasitic agent-32 (compound M9) is an analogue of Piperaquine and acts as a potent antiparasitic agent targeting plasmodium falciparum lactate dehydrogenase (Pf LDH) with a Pf3D7IC50 of 0.40 μM. It demonstrates significant activity against both the asexual and gametocyte stages of plasmodium falciparum. Its antimalarial effect is achieved through stable and specific non-covalent interactions at the NADH binding site. Antiparasitic agent-32 is applicable in malaria research.

Antiparasitic agent-31 (Compound LC-61) is a potent agent against Leishmania parasites, exhibiting an IC50 of 0.076 µM against intracellular Leishmania.

Antiparasitic agent-39 (Compound 14) is a selective antiparasitic derivative of Deferasirox that reduces mitochondrial membrane potential. It demonstrates antiparasitic activity against T. brucei, T. gambiense, L. Mexicana, T. gondii, B. divergens, and P. falciparum, with EC50 values of 4.2 nM, 10.4 nM, 52.0 nM, 17.0 nM, 41.2 nM, and 54.8 nM, respectively.

Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is a natural product functioning as an apoptosis and autophagy inducer. Possessing oral bioavailability, this compound exhibits diverse pharmacological effects including antiviral and antitumor activities through modulation of the GSK3β/β-catenin and p53 signaling pathways.

Pentagalloylglucose (Standard) is a reference standard for research and analysis in studies involving Pentagalloylglucose. 1, 2, 3, 4, 6-Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) and gallic acid from Pistacia lentiscus have antimutagenic and antioxidant activities. 2. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose (PGG) possesses potent anti-proliferative and anti-invasive effects, it also has inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity. 3. PGG may serve as a model for the development of new types of anti-diabetic and anti-metabolic syndrome therapeutics. 4. 1, 2, 3, 4, 6-Penta- O -galloyl-β- d -glucose has vasodilatory and anti-inflammatory effects, it dilates vascular smooth muscle and suppresses the vascular inflammatory process via endothelium-dependent nitric oxide (NO)/cGMP signaling. 5. 1, 2, 3, 4, 6-Penta-O-galloyl-beta-D-glucose can decrease the level of extracellular hepatitis B virus (HBV) (IC5, 1. microg/ml) in a dose-dependent manner, it also can reduce the HBsAg level by 25% at a concentration of 4 microg/ml; the gallate structure of PGG may play a critical role in the inhibition of anti-HBV activity, suggests that PGG could be a candidate for developing an anti-HBV agent. 6. 1, 2, 3, 4, 6-Penta-O-galloyl-β-D-glucose has anti-parasitic activity, displays an EC5 value of 67 μM, at least 6.6-fold more effective than the standard drug benznidazole against trypomastigote forms of T. cruzi.